The global hyperuricemia market, which includes urate-lowering therapeutics and diagnostic tools for managing elevated serum uric acid, is projected to expand from USD 4.78 billion in 2025 to USD 7.13 billion by 2031, achieving a compound annual growth rate of 6.89%. This growth is primarily fueled by the increasing worldwide prevalence of gouty arthritis and the expanding elderly population, who are more susceptible to metabolic disorders. Furthermore, widespread lifestyle changes, such as diets rich in purines and rising obesity rates, are significantly enlarging the patient pool that requires long-term pharmacological intervention, thus boosting demand for xanthine oxidase inhibitors and uricosuric agents. However, market expansion is frequently impeded by poor patient adherence to chronic therapy and the potential toxicity associated with existing first-line medications. For instance, the American College of Rheumatology reported in 2025 that the national average disability-adjusted life year rate for gout in the United States increased by 93.7% over the previous two decades, underscoring a growing burden that current management strategies have not fully alleviated. This deficiency in effective long-term care presents a significant challenge to the industry, as safety concerns and compliance issues restrict the consistent adoption of available treatments.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 4.78 Billion
Market Size 2031	USD 7.13 Billion
CAGR 2026-2031	6.89%
Fastest Growing Segment	Secondary
Largest Market	North America

Market Driver

The market's expansion is primarily driven by the rising global incidence of gout and asymptomatic hyperuricemia, fueled by an aging global population and evolving dietary patterns. As life expectancy increases, the geriatric population expands, leading to a higher frequency of crystal deposition diseases linked to reduced renal urate excretion. This demographic trend is compounded by the widespread adoption of high-purine diets and sedentary lifestyles, which accelerate metabolic dysfunction and broaden the patient pool requiring pharmacological intervention. A study published in PubMed Central in June 2025, for example, projects that the age-standardized prevalence rate of gout among older adults will rise to 3,628.85 per 100,000 population by 2050, confirming a sustained demand for effective management solutions. Concurrently, the escalating burden of chronic kidney disease (CKD) and metabolic disorders amplifies the necessity for hyperuricemia management, as elevated uric acid acts as both a complication and a potential progression factor for renal impairment. This urgency compels healthcare providers to prioritize aggressive urate monitoring and intervention in nephrology settings to prevent further kidney deterioration and manage cardiovascular risks. Scientific Reports, in November 2025, highlighted this critical overlap, revealing that 65.6% of non-dialysis chronic kidney disease patients presented with hyperuricemia. The commercial scale of this high-need segment is evidenced by Amgen's report in February 2025, stating that its targeted gout therapy, KRYSTEXXA, generated $1.2 billion in sales during 2024, demonstrating substantial market value in addressing severe and refractory cases.

Market Challenge

A primary impediment to the global hyperuricemia market's growth is the pervasive issue of poor patient adherence to chronic therapy, compounded by safety concerns associated with first-line medications. Despite an expanding potential patient base, the market's actual growth is significantly hindered because many individuals prematurely discontinue treatment. This high discontinuation rate often arises from the asymptomatic nature of hyperuricemia during inter-critical periods, which leads patients to underestimate the ongoing need for daily pharmacological intervention. Moreover, fears of toxicity, such as severe cutaneous reactions or cardiovascular risks linked to standard xanthine oxidase inhibitors, cause hesitation among both prescribers and patients, thereby limiting the volume of long-term prescriptions. This widespread lack of compliance directly impacts market performance by reducing prescription refills and diminishing the real-world efficacy of therapeutic agents. When treatment protocols are not sustained, patient outcomes stagnate, which prevents the widespread adoption of higher-value therapies. According to the American College of Rheumatology, 2025 survey data indicated that adherence to recommended dosing standards for urate-lowering therapy remains suboptimal, with less than 50% of treatment regimens fully aligning with the guidelines necessary to maintain target serum urate levels. This gap in effective utilization ensures that a substantial segment of the addressable market remains under-monetized, preventing the industry from fully capitalizing on the rising prevalence of the disease.

Market Trends

The treatment landscape is undergoing a significant transformation with the rapid emergence of novel selective URAT1 inhibitors, which are designed to address the efficacy limitations of existing xanthine oxidase inhibitors. Pharmaceutical developers are increasingly prioritizing high-potency uricosuric agents that directly target renal transporters to enhance uric acid excretion, offering a viable alternative for patients who fail to achieve target serum levels with standard oral therapies. This clinical shift is exemplified by the advancement of next-generation candidates engineered to maximize efficacy while minimizing renal toxicity. For instance, FierceBiotech reported in September 2025 that Atom Therapeutics' novel URAT1 inhibitor, ABP-671, achieved an impressive 91% response rate in reducing tophus diameter by week 28 in a pivotal Phase 2b/3 clinical trial. Simultaneously, there is a noticeable shift towards biologic combination therapies for refractory gout, specifically targeting the severe patient segment unresponsive to conventional oral medications. This trend involves integrating recombinant uricase enzymes with immunomodulatory technologies to mitigate anti-drug antibody formation and sustain therapeutic potency. These advanced regimens are crucial for rapidly reducing crystal deposits in chronic cases, thereby preventing irreversible joint damage. According to Pharmacy Times in January 2025, the novel combination therapy SEL-212 demonstrated a 56% response rate in maintaining serum urate levels below 6 mg/dL in high-dose cohorts, validating its potential to address significant unmet needs in the refractory setting.

Key Market Players

Takeda Pharmaceutical Company Limited
AstraZeneca plc
Horizon Therapeutics plc
Novartis AG
Sanofi S.A.
Teijin Pharma Limited
Mylan N.V.
Hikma Pharmaceuticals PLC
Dr. Reddy's Laboratories Ltd.
Sun Pharmaceutical Industries Ltd

Report Scope

In this report, the Global Hyperuricemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hyperuricemia Market, By Type

Primary
Secondary

Hyperuricemia Market, By Drug Type

Xanthine Oxidase Inhibitors
Nonsteroidal Anti-Inflammatory Drugs
Corticosteroids
Others

Hyperuricemia Market, By Route of Administration

Oral
Injectable

Hyperuricemia Market, By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Hyperuricemia Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hyperuricemia Market.

Available Customizations:

Global Hyperuricemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hyperuricemia Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Primary, Secondary)
- 5.2.2. By Drug Type (Xanthine Oxidase Inhibitors, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Others)
- 5.2.3. By Route of Administration (Oral, Injectable)
- 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.5. By Region
- 5.2.6. By Company (2025)
5.3. Market Map

6. North America Hyperuricemia Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Drug Type
- 6.2.3. By Route of Administration
- 6.2.4. By Distribution Channel
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Hyperuricemia Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Drug Type
    - 6.3.1.2.3. By Route of Administration
    - 6.3.1.2.4. By Distribution Channel
- 6.3.2. Canada Hyperuricemia Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Drug Type
    - 6.3.2.2.3. By Route of Administration
    - 6.3.2.2.4. By Distribution Channel
- 6.3.3. Mexico Hyperuricemia Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Drug Type
    - 6.3.3.2.3. By Route of Administration
    - 6.3.3.2.4. By Distribution Channel

7. Europe Hyperuricemia Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Drug Type
- 7.2.3. By Route of Administration
- 7.2.4. By Distribution Channel
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Hyperuricemia Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Drug Type
    - 7.3.1.2.3. By Route of Administration
    - 7.3.1.2.4. By Distribution Channel
- 7.3.2. France Hyperuricemia Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Drug Type
    - 7.3.2.2.3. By Route of Administration
    - 7.3.2.2.4. By Distribution Channel
- 7.3.3. United Kingdom Hyperuricemia Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Drug Type
    - 7.3.3.2.3. By Route of Administration
    - 7.3.3.2.4. By Distribution Channel
- 7.3.4. Italy Hyperuricemia Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Drug Type
    - 7.3.4.2.3. By Route of Administration
    - 7.3.4.2.4. By Distribution Channel
- 7.3.5. Spain Hyperuricemia Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Drug Type
    - 7.3.5.2.3. By Route of Administration
    - 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Hyperuricemia Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Drug Type
- 8.2.3. By Route of Administration
- 8.2.4. By Distribution Channel
- 8.2.5. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Hyperuricemia Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Drug Type
    - 8.3.1.2.3. By Route of Administration
    - 8.3.1.2.4. By Distribution Channel
- 8.3.2. India Hyperuricemia Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Drug Type
    - 8.3.2.2.3. By Route of Administration
    - 8.3.2.2.4. By Distribution Channel
- 8.3.3. Japan Hyperuricemia Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Drug Type
    - 8.3.3.2.3. By Route of Administration
    - 8.3.3.2.4. By Distribution Channel
- 8.3.4. South Korea Hyperuricemia Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Drug Type
    - 8.3.4.2.3. By Route of Administration
    - 8.3.4.2.4. By Distribution Channel
- 8.3.5. Australia Hyperuricemia Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Drug Type
    - 8.3.5.2.3. By Route of Administration
    - 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Hyperuricemia Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Drug Type
- 9.2.3. By Route of Administration
- 9.2.4. By Distribution Channel
- 9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Hyperuricemia Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Drug Type
    - 9.3.1.2.3. By Route of Administration
    - 9.3.1.2.4. By Distribution Channel
- 9.3.2. UAE Hyperuricemia Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Drug Type
    - 9.3.2.2.3. By Route of Administration
    - 9.3.2.2.4. By Distribution Channel
- 9.3.3. South Africa Hyperuricemia Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Drug Type
    - 9.3.3.2.3. By Route of Administration
    - 9.3.3.2.4. By Distribution Channel

10. South America Hyperuricemia Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Drug Type
- 10.2.3. By Route of Administration
- 10.2.4. By Distribution Channel
- 10.2.5. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Hyperuricemia Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Drug Type
    - 10.3.1.2.3. By Route of Administration
    - 10.3.1.2.4. By Distribution Channel
- 10.3.2. Colombia Hyperuricemia Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Drug Type
    - 10.3.2.2.3. By Route of Administration
    - 10.3.2.2.4. By Distribution Channel
- 10.3.3. Argentina Hyperuricemia Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Drug Type
    - 10.3.3.2.3. By Route of Administration
    - 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Hyperuricemia Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Takeda Pharmaceutical Company Limited
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. AstraZeneca plc
15.3. Horizon Therapeutics plc
15.4. Novartis AG
15.5. Sanofi S.A.
15.6. Teijin Pharma Limited
15.7. Mylan N.V.
15.8. Hikma Pharmaceuticals PLC
15.9. Dr. Reddy's Laboratories Ltd.
15.10. Sun Pharmaceutical Industries Ltd

16. Strategic Recommendations

17. About Us & Disclaimer

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

SELECT AN OPTION